UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Abbott Laboratories
In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Abbott Laboratories (NYSE: ABT), but lowered its price target from $87.00 to $39.00.
Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”
Abbott Laboratories closed on Tuesday at $33.36.
Latest Ratings for ABT
|Jan 2015||Stifel Nicolaus||Maintains||Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.